多发性骨髓瘤蛋白酶体抑制剂类化学仿制药药学研究考虑OA

Proteasome inhibitors have become key drugs in the targeted therapy of multiple myeloma in current clinical applications.Based on the publicly available information on the domestic and foreign official websites of drug regulatory authorities regarding currently marketed proteasome inhibitor drugs,such as bortezomib for injection,carfilzomib for injection,and ixazomib citrate capsules,this article proposes the key points of attention in the research of drug substances and drug products for these three agents in pharmaceutical development,in order to promote the marketing of generic drugs.